Climb Bio Shares Rise On CLYM116 Data Supporting Every-12-Week Dosing

Climb Bio (CLYM) stock fell 7% to $14.00 in pre-market trading after releasing Phase 1 clinical data for CLYM116, showing near-complete APRIL protein suppression and sustained IgA reductions. The decline follows a 'buy the rumor, sell the news' pattern, with investors taking profits after the data release. The company's Phase 2 trial data is not expected until 2027, contributing to the pullback. The broader market showed modest gains, with the S&P 500, Dow Jones, and Nasdaq up 0.3%, 0.6%, and 0.

Climb Bio (CLYM) reported positive Phase 1 data for CLYM116, showing a 29-day half-life, 90% APRIL suppression, and 60-75% IgA suppression. The drug was well-tolerated. Phase 2 trial data is expected in H1 2027, with Phase 3 initiation planned for 2027. The company will host a webcast on September 3.

Climb Bio, Inc. (CLYM) shares rose 17% after reporting positive Phase 1 trial results for CLYM116, its anti-APRIL monoclonal antibody. The drug showed near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression, with a half-life of 29 days. The trial enrolled 46 subjects and reported no serious adverse events. The company plans to present additional data in Q4 2026 and anticipates Phase 2 trial results in H1 2027.

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2

NeuroSense Therapeutics (NRSN) announced a redesigned development strategy for PrimeC in ALS, aiming to accelerate regulatory approval and reduce costs. The strategy includes AI-enabled formulation analysis, a comparative study against edaravone, and an optimized Phase 3 trial design. The company has received FDA clearance and is targeting a Canadian regulatory submission by December 2026. PrimeC is an investigational oral therapy combining ciprofloxacin and celecoxib.

Pulnovo Medical, a Medtronic subsidiary, reported positive results from its PADN-HF-PH trial in PH-LHD patients, showing a 51% reduction in clinical worsening risk and improved functional capacity. The trial was presented at the ESC Congress 2026 and published in NEJM. PADN has received regulatory approvals in 12 countries and is being expanded to treat WHO Group 2 pulmonary hypertension. Medtronic's stock is currently trading at EUR 79.22, down 2.77%.